Results 31 to 40 of about 3,987 (159)
Real-life cost-effectiveness of benralizumab in patients with severe asthma
Respiratory Research, 2021 Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems.A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon +10 moredoaj +1 more sourceBenralizumab for the Prevention of COPD Exacerbations [PDF]
New England Journal of Medicine, 2019 The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on ...Criner Gerard J, Celli Bartolome R, Brightling Christopher E, Agusti Alvar, Papi Alberto, Singh Dave, Sin Don D, Vogelmeier Claus F, Sciurba Frank C, Bafadhel Mona, Backer Vibeke, Kato Motokazu, Ramírez-Venegas Alejandra, Wei Yu-Feng, Bjermer Leif, Shih Vivian H, Jison Maria, O'Quinn Sean, Makulova Natalya, Newbold Paul, Goldman Mitchell, Martin Ubaldo J, Kollaborációs szervezet: GALATHEA Study Investigators, Kollaborációs szervezet: TERRANOVA Study Investigators, Bálint Beatrix +24 moreopenaire +10 more sourcesThe International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
Allergy, EarlyView.ABSTRACT
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff, M. M. Abuzakouk, M. S. Agcaoili‐De Jesus, R. C. Agondi, M. Al‐Ahmad, A. A. Alangari, H. Alhameli, C. D. Alonso Bello, S. Alshareef, S. Al‐Tamemi, S. Altrichter, H. Al Wahshi, S. Aquilina, M. Araújo, R. Arnaout, R. Asero, B. Ballmer‐Weber, C. Bangert, A. Bauer, M. Ben‐Shoshan, J. A. Bernstein, C. Bindslev‐Jensen, M. Bizjak, I. Boccon‐Gibod, H. Bonnekoh, L. Bouillet, K. Brockow, Z. Brzoza, M. Bulatović Ćalasan, A. Bulkhi, T. Buttgereit, A. Bygum, T. Caballero, O. Calderon, R. Campos, M. Cancian, E. Carne, M. A. Castor, I. Cerecedo, T. Çetinarslan, I. Cherrez‐Ojeda, N. Chkhikvadze, H. J. Chong‐Neto, K. Choo, G. Christoff, C.‐Y. Chu, K. Ciupka, N. Conlon, C. Costa, T. Craig, P. Criado, I. Danilycheva, R. Darlenski, E. De Arruda Chaves, L. de Montjoye, M. S. Doutre, A. Du‐Thanh, D. Ebo, S. Elkhalifa, S. Elmariah, T. El‐Shanawany, L. F. Ensina, R. Ertaş, R. Fachini Jardim Criado, M. Ferrer, S. Ferrucci, J. S. Fok, D. Fomina, L. Fonacier, G. Fouda, I. Francescantonio, A. Fukunaga, C. A. Galvan Calle, E. Garcia, K. Gáspár, A. Gelincik, S. Geng, K. Godse, M. Gonçalo, M. Gotua, C. Grattan, M. Grosber, G. Guidos Fogelbach, M. Guilarte, R. Guillod, E. Hamelmann, J. Hawkes, K. Hayama, R. Heuer, M. Hide, W. Hoetzenecker, N. Inomata, H.‐R. Kang, A. Kaplan, A. Kapp, M. Karam, A. Kasperska‐Zajac, C. H. Katelaris, A. Kessel, M. Khoshkhui, B. Kim, T. Kinaciyan, E. Kocatürk, M. Kolacinska‐Flont, P. Kolkhir, G. N. Konstantinou, M. Kosnik, D. Krasowska, K. Kulthanan, M. S. Kumaran, I. Kuprys‐Lipinska, M. Labrador, J. I. Larco, D. Larenas‐Linnemann, E. Latysheva, E. Lazaridou, P. H. Li, H. Lima, U. Lippert, M. Magerl, M. Makris, J. Alves Marcelino, A. V. Marzano, I. Medina, R. Meshkova, D. Micallef, R. Mohammed Ali, C. G. Mortz, M. Munoz, H. N. G. Oude Elberink, A. Nakonechna, I. Nasr, A. Nast, E. Netchiporouk, E. Nettis, S. Nieto, I. Ogueta Canales, T.‐L. Okas, R. L. Orfali, E. Özkaya, C. Parisi, A. Pennitz, R. Pawankar, M. P. Pereira, J. Peter, E. Petkova, P. D. Pigatto, I. Podder, T. Popov, G. Porebski, P. Pyatilova, G. D. Ramon, H. A. Ratti Sisa, M. Recto, K. Ress, K. Ridge, M. Riedl, C. Ritchie, N. Rosario Filho, I. Rosmaninho, M. Rudenko, M. Rukhadze, K. Rutkowski, V. Sabato, U. M. Sahiner, S. Saini, F. Saleh Al Sabbagh, A. Salman, F. Salvo, J. Sanchez, A. Santucci, S. Schliemann, P. Schmid‐Grendelmeier, B. E. Sekerel, F. Serpa, F. Sheikh, J. Sheikh, H. Shendi, F. Siebenhaar, M. Sonomjamts, A. Soria, B. Sousa Pinto, M. Staevska, P. Staubach, M. Stephan, K. Stevanovic, L. Stingeni, M. Stobiecki, Ö. Su Küçük, G. Sussman, A. Szegedi, S. Takahagi, A. Tanaka, N. Teovska Mitrevska, S. F. Thomsen, E. Toubi, F. Tsatsou, M. Turk, Z. Vadasz, A. Valerieva, S. Valle, M. v. Doorn, B. Veleiro Perez, C. E. Vera Ayala, C. Vestergaard, R. J. Vieira, C. W. Maruta, B. Wedi, R. N. Werner, E. W. Y. Yap, P. Xepapadaki, Y. Xiang, Y.‐M. Ye, P. Yong, G. Yosipovitch, A. Z. J. Zalewska‐Janowska, C. Zeyen, Z. Zhao, M. Metz, A. M. Giménez‐Arnau +221 morewiley +1 more sourceTargeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice
Allergy, EarlyView.ABSTRACT
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui +7 morewiley +1 more sourceCharacteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort
Journal of Asthma and Allergy, 2018 Michel Aubier,1–4 Gabriel Thabut,1–3,5 Caroline Fabry-Vendrand6 1Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France; 2Faculty of Medicine, Paris Diderot University, Paris, France; 3Laboratory of Excellence,Aubier M, Thabut G, Fabry-Vendrand Cdoaj Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Frontiers in Allergy, 2022 BackgroundSevere eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation.Maria D'Amato, Francesco Menzella, Elena Altieri, Elena Bargagli, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Fabiano Di Marco, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Gianenrico Senna, Alessandra Vultaggio, Alessandra Ori, Lucia Simoni, Silvia Boarino, Gianfranco Vitiello, Maria Aliani, Stefano Del Giacco +27 moredoaj +1 more sourceEfficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial
Allergy, EarlyView.Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang +18 morewiley +1 more source
